Inventive step

I reported last year on the three-part article series published in EPI Information by Tamaris Bucher, Principal Patent Attorney at Novartis, on the EPO’s approach to assessing inventive step for…

Key Takeaway: The Unified Patent Court is no longer an experiment. With filings up sharply and practitioners increasingly confident in using the system, litigation before the UPC is developing its…

The final week of July usually produces a flurry, and sometimes an avalanche, of decisions from the English Courts as Judges attempt to clear their desks before the holiday period.  This year was no…

Defining antibodies by functional features is not always straightforward at the EPO. T326/22 is a nice example of how this can be achieved.       To briefly recap the standard EPO approach, an…

One of the most highly debated issues at the UPC before its commencement was the question, how the UPC would deal with validity of patents – would it essentially take over the EPO’s course? Or would…

On 9 January 2025 I reported on Parts 1 and 2 of a three-part article in EPI Information by Tamaris Bucher, a Principal Patent Attorney at Novartis Pharma AG, on the current approach to antibody…

The Russian Patent Office (Rospatent) has introduced new provisions relating to the assessment of patentability of “use” inventions. Background On September 27, 2024, the Russian Ministry of Economic…

The festive period normally leads to a slight slow-down in work in Europe and as such, it can provide the opportunity to catch up on wider reading as well as to grab a little rest.  In between the…

On 30 October 2024, the District Court of the Hague handed down two merits decisions on the widely litigated apixaban patent of Bristol-Myers Squibb (see here and here - Dutch language versions). EP…